PLEVA, Leos, Pavel KUKLA, Jana ZAPLETALOVA and Ota HLINOMAZ. In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters. cor et Vasa. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, vol. 63, No 4, p. 442-447. ISSN 0010-8650. Available from: https://dx.doi.org/10.33678/cor.2021.013.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters
Authors PLEVA, Leos (203 Czech Republic, guarantor), Pavel KUKLA (203 Czech Republic), Jana ZAPLETALOVA (203 Czech Republic) and Ota HLINOMAZ (203 Czech Republic, belonging to the institution).
Edition cor et Vasa, AMSTERDAM, ELSEVIER SCIENCE BV, 2021, 0010-8650.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/21:00124158
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.33678/cor.2021.013
UT WoS 000694709000003
Keywords in English In-stent restenosis; Paclitaxel-eluting balloon; Seal-wing PEB
Tags 14110115, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 15/2/2022 10:53.
Abstract
Objectives: We aimed to compare the long-term clinical outcomes of seal-wing and iopromide-coated pacli-taxel eluting balloon catheters (PEB) in the treatment of bare-metal stent restenosis (BMS-ISR). Methods: A 3-year clinical follow-up of 132 patients with BMS-ISR was performed, of whom 64 were treated with seal-wing PEB; the control group consisted of 68 patients from iopromide-coated PEB branch of the previous TIS study. The primary endpoint was the occurrence of major adverse cardiac events (MACE; cardio-vascular [CV] death, myocardial infarction [MI], or target vessel revascularization [TVR]). Results: Compared to iopromide-coated PEB, the incidence of 3-year MACE was significantly higher (40.6% vs. 19.1%; p = 0.008) in the seal-wing PEB group; a similar difference was achieved when comparing the need for TVR (26.9% vs. 8.8%; p = 0.011). The event-free survival in the iopromide-coated PEB group was signifi-cantly longer (p = 0.021). There were no differences in cardiovascular mortality (4.7% vs. 5.9%; p = 1.000), occurrence of MI (6.3% vs. 4.4%; p = 0.712), definite ST (0% vs. 2.9%; p = 0.497) or repeated MACE (4.7% vs. 1.5%; p = 0.354) between the two groups. Conclusion: Compared to iopromide-coated PEB, the use of seal-wing PEB in the treatment of BMS-ISR is as-sociated with a significantly higher 3-year incidence of MACE and TVR
PrintDisplayed: 29/7/2024 05:20